Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Evgen Pharma soars on news of US patent grant

“This patent grant extends our intellectual property protection in the world's largest pharmaceutical market”
patents folder
Evgen has patents pending in several other territories across the globe

Shares in Evgen Pharma plc (LON:EVG) soared on Tuesday afternoon after the drug developer revealed it had been granted a US patent which “significantly broadens and extends [its] intellectual property” around its lead product SFX-01.

Shares were up 14% to 25p shortly before the close of play in London.

The new patent covers the manufacturing process of SFX-01 – a synthetic version of the naturally occurring compound sulforaphane – and runs until 2033.

“This patent grant extends our intellectual property protection in the world's largest pharmaceutical market and is the first of a potentially broad geographical spread of patents that are pending in Europe, Japan, India, China, Canada, Brazil and Australia,” said chief executive Stephen Franklin.

Under the terms of the licence agreement with PharmAgra Labs Inc – the US lab which invented the compound – Evgen holds the exclusive worldwide rights to the patent.

Evgen is currently conducting two phase II trials of SFX-01; one in advanced breast cancer and the other in a type of stroke called subarachnoid haemorrhage.

Today’s patent grant comes a day after Evgen signed a services agreement with a consortium of Cheshire-based drug development firms.

The group aims to help clients turn promising molecules and compounds into valued medicines, which Evgen hopes to do with SFX-01.

View full EVG profile View Profile

Evgen Pharma Timeline

Article
October 21 2015

Related Articles

tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use